Product Overview
[Drug Name]
Generic Name: Valsartan Dispersible Tablets
Trade Name: Senping Valsartan Dispersible Tablets 80mg*10 Tablets
Pinyin Code: SenPing ZuoShaTanFenSanPian 80mg*10 Tablets
[Main Ingredient]
The main ingredient of this product is valsartan. Chemical Name: N-(1-Oxopentyl)-N-{[2'-(1H-tetrazol-5-yl)-[1,1'-diphenyl]-4-yl]methyl)-L-valine. Molecular Formula: C24H29N5O3. Molecular Weight: 435.52
[Properties]
This product is white or off-white tablets.
[Indications/Main Functions]
Treatment of mild to moderate essential hypertension.
[Specifications]
80mg*10 tablets
[Dosage and Administration]
Recommended dose: 80mg once daily. Dosage is not affected by race, age, or gender. It can be taken with or without food (see Absorption). It is recommended to take the drug at the same time each day (e.g., morning). A definitive antihypertensive effect is achieved within two weeks, and maximum efficacy is achieved after four weeks. If the antihypertensive effect is unsatisfactory, the daily dose can be increased to 160 mg, or a diuretic can be added. No dose adjustment is required for patients with renal insufficiency (see contraindications for severe renal failure) or non-biliary, non-cholestatic hepatic insufficiency. Valsartan can be used in combination with other antihypertensive drugs.
[Adverse Reactions]
See the package insert for details.
[Contraindications]
1. Hypersensitivity to any of the ingredients. 2. Pregnancy (see Pregnancy and Lactation). 3. There is no experience with this drug in patients with severe renal failure (creatinine clearance <10 mcg/min).
[Precautions]
1. Hyponatremia and/or hypovolemia. In rare cases, patients with severe sodium and/or hypovolemia (e.g., those taking high-dose diuretics) may experience symptomatic hypotension when starting treatment with this drug. Before starting this medication, correct hyponatremia and/or hypovolemia, or reduce the diuretic dose. If hypotension occurs, place the patient in a supine position and administer normal saline intravenously if necessary. Resume treatment with this medication after blood pressure stabilizes. 2. Renal Artery Stenosis: In 12 patients with secondary renovascular hypertension due to unilateral renal artery stenosis, 4-day use of this medication did not cause significant changes in renal hemodynamics or creatinine urea nitrogen (BUN). Because other drugs that act on the RAAS may increase BUN and creatinine in patients with unilateral or bilateral renal artery stenosis, monitoring is recommended to ensure safety. 3. Renal Impairment: No dose adjustment is required in patients with renal insufficiency. The valsartan dose should not exceed 80 mg/day in patients with mild to moderate hepatic impairment. Valsartan is primarily excreted unchanged in the bile, and excretion is reduced in patients with biliary obstruction (see Pharmacokinetics). Caution should be exercised in such patients using this medication. As with other antihypertensive drugs, patients taking this medication should exercise caution when driving or operating machinery.
